Synergistic induction of apoptosis in B-cell chronic lymphocytic leukemia cells after treatment with all-trans retinoic acid in combination with interleukin-21 and rituximab

J Cancer Res Ther. 2016 Oct-Dec;12(4):1278-1283. doi: 10.4103/0973-1482.184522.

Abstract

Aim: B-cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in the Western world and characterized by the progressive expansion of malignant B lymphocytes in peripheral blood. In spite of advances in sciences to recognize the number of effective agents for the treatment of chronic lymphocytic leukemia (CLL), this leukemia is thought as incurable one. Introducing a new therapy that has a direct effect on B-CLL lymphocytes and no cytotoxic effects on the other cells is a great wish.

Materials and methods: Twenty-one patients with B-CLL were enrolled in the study. Peripheral blood mononuclear cells (PBMCs) were isolated from patients' blood samples and were further treated with all-tans retinoic acid (ATRA), interleukin (IL-21), and rituximab at concentrations of 30 ng/ml, 25 ng/ml, and 4 μg/ml, respectively. ATRA, IL21, and rituximab were used alone or in various combinations and their effects on apoptosis were measured using annexin V-fluorescein isothiocyanate apoptosis detection kit.

Result: Treatment of the patients' cells with IL21 and rituximab showed a synergistic effect on the induction of apoptosis, in comparison with untreated CLL cells (P < 0.05). The induction of apoptosis by ATRA in combination with IL21 and rituximab were significantly increased compared to untreated CLL cells as a negative control (P < 0.01).

Conclusion: Treatment of patients' PBMCs by ATRA in combination with IL21 and rituximab and also IL21 in combination with rituximab showed synergistic induction of apoptosis compared to untreated CLL cells as a negative control (P < 0.01). It seems that ATRA in combination with IL21 and rituximab activate different pathways of apoptosis (extrinsic pathway, intrinsic pathway, and granzyme B pathway).

MeSH terms

  • Adult
  • Aged
  • Antigens, CD19 / metabolism
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Biomarkers
  • CD5 Antigens / metabolism
  • Cell Line, Tumor
  • Disease Progression
  • Drug Synergism
  • Female
  • Humans
  • Interleukins / pharmacology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Rituximab / pharmacology*
  • Tretinoin / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Antigens, CD19
  • Antineoplastic Agents
  • Biomarkers
  • CD5 Antigens
  • Interleukins
  • Rituximab
  • Tretinoin
  • interleukin-21